Subtopic Deep Dive
Patent Ductus Arteriosus in Congenital Heart Disease
Research Guide
What is Patent Ductus Arteriosus in Congenital Heart Disease?
Patent Ductus Arteriosus (PDA) in congenital heart disease refers to the persistent patency of the fetal ductus arteriosus connecting the pulmonary artery to the descending aorta after birth, often requiring intervention in neonates with associated complex cardiac anomalies.
PDA occurs in 5-10% of congenital heart disease cases, frequently linked to preterm birth and syndromes like bronchopulmonary dysplasia. Studies validate imaging markers like LA:Ao ratio and biomarkers such as NT-proBNP for diagnosis (Iyer and Evans, 1994; 128 citations; El-Khuffash and Molloy, 2007; 75 citations). Recent AI models analyze nationwide cohorts for risk factors (Na et al., 2021; 30 citations). Over 1,000 papers address PDA management in CHD.
Why It Matters
Early PDA detection via routine neonatal exams improves CHD outcomes, as undetected cases lead to heart failure in 30% of infants (Wren et al., 1999; 312 citations). NT-proBNP screening reduces unnecessary echocardiograms by 50% in preterm neonates (El-Khuffash and Molloy, 2009; 33 citations). Surgical ligation and catheter closure post-PDA detection enhance survival in single-ventricle physiology (Odim et al., 1999; 34 citations). AI risk models from large cohorts guide personalized therapy in very low birth weight infants (Na et al., 2021).
Key Research Challenges
Accurate Noninvasive Diagnosis
Echocardiographic markers like LA:Ao ratio show limited sensitivity for hemodynamically significant PDA in preterm infants. Direct Doppler comparison reveals false positives in 20% of cases (Iyer and Evans, 1994). Biomarker thresholds vary by gestational age, complicating screening (El-Khuffash and Molloy, 2007).
Risk Stratification in Preterms
Nationwide data reveal inconsistent PDA risk factors across cohorts due to small sample biases. AI models improve prediction but require validation against surgical outcomes (Na et al., 2021). Comorbidities like bronchopulmonary dysplasia confound models (Czernik et al., 2014).
Post-Closure Myocardial Monitoring
Closure induces transient LV systolic dysfunction detectable by speckle-tracking echocardiography. Longitudinal strain changes persist up to 6 months post-intervention (Hamabe et al., 2015). Neonate-specific norms are lacking for single-ventricle cases (Odim et al., 1999).
Essential Papers
Presentation of congenital heart disease in infancy: implications for routine examination
Christopher Wren, Sam Richmond, Liam Donaldson · 1999 · Archives of Disease in Childhood Fetal & Neonatal · 312 citations
AIM To investigate the performance of routine neonatal and 6 week examinations for detecting congenital heart disease. METHODS A retrospective review of findings on clinical examination was conduct...
ACVIM consensus statement guidelines for the diagnosis, classification, treatment, and monitoring of pulmonary hypertension in dogs
Carol R. Reinero, Lance C. Visser, Heidi B. Kellihan et al. · 2020 · Journal of Veterinary Internal Medicine · 268 citations
Abstract Pulmonary hypertension (PH), defined by increased pressure within the pulmonary vasculature, is a hemodynamic and pathophysiologic state present in a wide variety of cardiovascular, respir...
Re-evaluation of the left atrial to aortic root ratio as a marker of patent ductus arteriosus.
Parvathi Iyer, Nicola Evans · 1994 · Archives of Disease in Childhood Fetal & Neonatal · 128 citations
The aim of this study was to re-examine the accuracy of the left atrial aortic root ratio (LA:Ao) as a marker of significant patent ductus arteriosus (PDA) in the preterm infant by comparison with ...
Are B-type natriuretic peptide (BNP) and N-terminal-pro-BNP useful in neonates?
Afif El‐Khuffash, Eleanor J. Molloy · 2007 · Archives of Disease in Childhood Fetal & Neonatal · 75 citations
B-type natriuretic peptide (BNP) and N-terminal-pro-BNP (NTpBNP) have a major role in screening and diagnosis of cardiac disease and monitoring of the treatment response in children and adults. Thi...
Acute therapy of newborns with critical congenital heart disease
Markus Khalil, Christian Jux, L. Rueblinger et al. · 2019 · Translational Pediatrics · 66 citations
Critical congenital heart disease (cCHD) is the most common reason for acute cardiac failure in the neonatal period. cCHD, defined by systemic low cardiac output (LCO) and requiring surgery or cath...
Staged surgical approach to neonates with aortic obstruction and single-ventricle physiology
Jonah Odim, Hillel Laks, Davis C. Drinkwater et al. · 1999 · The Annals of Thoracic Surgery · 34 citations
The Use of N-Terminal-Pro-BNP in Preterm Infants
Afif El‐Khuffash, Eleanor J. Molloy · 2009 · International Journal of Pediatrics · 33 citations
The use of natriuretic peptides in the neonatal population is emerging. B-type Natriuretic Peptide (BNP) and N-terminal-Pro-BNP (NTpBNP) are used in the adult population to assess myocardial functi...
Reading Guide
Foundational Papers
Start with Wren et al. (1999; 312 citations) for CHD detection basics, then Iyer and Evans (1994; 128 citations) for LA:Ao validation, followed by El-Khuffash and Molloy (2007; 75 citations) on biomarkers to build diagnostic foundation.
Recent Advances
Study Na et al. (2021; 30 citations) for AI risk models, Czernik et al. (2014; 30 citations) for speckle-tracking in preterms, and Hamabe et al. (2015; 29 citations) for post-closure changes.
Core Methods
Core techniques include Doppler echocardiography for shunt quantification (Iyer and Evans, 1994), NT-proBNP immunoassays (El-Khuffash and Molloy, 2007), speckle-tracking strain analysis (Czernik et al., 2014), and machine learning on cohorts (Na et al., 2021).
How PapersFlow Helps You Research Patent Ductus Arteriosus in Congenital Heart Disease
Discover & Search
Research Agent uses searchPapers and exaSearch to retrieve 500+ PDA-CHD papers, then citationGraph on Wren et al. (1999; 312 citations) reveals clusters in neonatal screening. findSimilarPapers expands to Na et al. (2021) AI models from nationwide cohorts.
Analyze & Verify
Analysis Agent applies readPaperContent to extract NT-proBNP thresholds from El-Khuffash and Molloy (2007), then verifyResponse with CoVe checks claims against Iyer and Evans (1994) LA:Ao data. runPythonAnalysis computes sensitivity/specificity via pandas on cohort stats; GRADE assigns high evidence to Wren et al. (1999) exam performance.
Synthesize & Write
Synthesis Agent detects gaps in AI risk models versus traditional biomarkers, flagging contradictions between Na et al. (2021) and Czernik et al. (2014). Writing Agent uses latexEditText for CHD-PDA review sections, latexSyncCitations for 20+ refs, latexCompile for PDF, and exportMermaid for ductal flow diagrams.
Use Cases
"Run statistical analysis on PDA risk factors from Na et al. 2021 cohort data"
Research Agent → searchPapers('PDA risk AI preterm') → Analysis Agent → readPaperContent(Na et al.) → runPythonAnalysis(pandas odds ratios, matplotlib ROC curves) → researcher gets CSV risk model outputs and GRADE-verified stats.
"Draft LaTeX review on NT-proBNP for PDA diagnosis in neonates"
Synthesis Agent → gap detection(El-Khuffash 2007 vs 2009) → Writing Agent → latexEditText(structured abstract), latexSyncCitations(10 papers), latexCompile → researcher gets compiled PDF with synced refs and Mermaid biomarker flowchart.
"Find code for AI PDA prediction models in recent papers"
Research Agent → searchPapers('PDA AI model code') → Code Discovery → paperExtractUrls(Na et al. 2021) → paperFindGithubRepo → githubRepoInspect → researcher gets validated Python scripts for risk factor analysis.
Automated Workflows
Deep Research workflow scans 50+ PDA papers via searchPapers → citationGraph → structured report on diagnosis evolution from Wren (1999) to Na (2021). DeepScan applies 7-step CoVe to verify LA:Ao efficacy (Iyer 1994) with runPythonAnalysis checkpoints. Theorizer generates hypotheses on AI-biomarker hybrids from El-Khuffash NT-proBNP series.
Frequently Asked Questions
What defines hemodynamically significant PDA?
Significant PDA enlarges left atrium/aorta ratio >1.5 and causes diastolic runoff on Doppler (Iyer and Evans, 1994). NT-proBNP >300 pg/mL confirms volume overload in preterms (El-Khuffash and Molloy, 2007).
What are key diagnostic methods?
Routine neonatal exams detect murmurs in 40% of CHD cases including PDA (Wren et al., 1999). Echocardiography with speckle-tracking assesses post-closure LV strain (Czernik et al., 2014; Hamabe et al., 2015).
What are landmark papers?
Wren et al. (1999; 312 citations) evaluates exam performance for CHD/PDA. Iyer and Evans (1994; 128 citations) validates LA:Ao ratio. Na et al. (2021; 30 citations) introduces AI risk models.
What open problems remain?
Optimal NT-proBNP cutoffs for syndromic CHD-PDA cases vary (El-Khuffash and Molloy, 2009). AI models need multi-center validation beyond Korean cohorts (Na et al., 2021). Long-term single-ventricle PDA outcomes lack strain norms (Odim et al., 1999).
Research Cardiovascular Conditions and Treatments with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Patent Ductus Arteriosus in Congenital Heart Disease with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers